IMARA (IMRA) Stock Price, News & Analysis

Company Overview

IMARA Inc., a clinical-stage biopharmaceutical company, develops and commercializes therapeutics for patients with rare genetic disorders of hemoglobin. Its lead product candidate is IMR-687, an oral and once-a-day therapeutic that is in Phase 2b clinical trials for the treatment of sickle cell disease and ß-thalassemia. The company also develops IMR-261, an oral and clinical-ready activator of nuclear factor erythroid 2-related factor 2 for the treatment of hemoglobinopathies, iron disorders, and potentially other areas. IMARA Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.

Key Stats

• Today's Range: $55.64 to $55.64
• 50-Day Range: $6.32 to $25.28
• 52-Week Range: $0.97 to $6.32
• Volume: 48 shs
• Average Volume: 138,364 shs
• Market Capitalization: $1.46 billion
• P/E Ratio: 1,112.93
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

IMRA Stock Analysis - Frequently Asked Questions

How were IMARA's earnings last quarter?

IMARA Inc. (NASDAQ:IMRA) issued its earnings results on Tuesday, November, 9th. The company reported ($2.20) EPS for the quarter, beating the consensus estimate of ($3.64) by $1.44.

When did IMARA's stock split?

IMARA shares reverse split before market open on Friday, February 24th 2023. The 1-4 reverse split was announced on Friday, February 24th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Friday, February 24th 2023. An investor that had 100 shares of stock prior to the reverse split would have 25 shares after the split.

When did IMARA IPO?

IMARA (IMRA) raised $76 million in an initial public offering (IPO) on Thursday, March 12th 2020. The company issued 4,500,000 shares at $16.00-$18.00 per share. Morgan Stanley, Citigroup and SVB Leerink acted as the underwriters for the IPO.

What other stocks do shareholders of IMARA own?

Based on aggregate information from My MarketBeat watchlists, some other companies that IMARA investors own include NIO (NIO), Novavax (NVAX), NVIDIA (NVDA), Axsome Therapeutics (AXSM), Alibaba Group (BABA), AMC Entertainment (AMC) and BioXcel Therapeutics (BTAI).

Company Calendar

• Last Earnings: 11/09/2021
• Today: 4/26/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:IMRA
• CIK: 1672619
• Web: www.imaratx.com
• Phone: N/A
• Fax: N/A
• Employees: 41
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): $0.05
• Trailing P/E Ratio: 1,112.93
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $1.49 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: 2.12%
• Return on Assets: 2.00%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 48.98
• Quick Ratio: 48.98

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: $0.74 per share
• Price / Cash Flow: 75.24
• Book Value: $3.44 per share
• Price / Book: 16.17

Miscellaneous

• Outstanding Shares: 26,234,000
• Free Float: 16,449,000
• Market Cap: $1.46 billion
• Optionable: Not Optionable
• Beta: 1.09